Table 2.
Laboratory findings of patients with macrophage activation syndrome
| Tocilizumab | Historic cohort | |||||
|---|---|---|---|---|---|---|
| Full-blown (n = 2) | Possible (n = 10) | All (n = 12) | Full-blown (n = 10) | Possible (n = 8) | All (n = 18) | |
| Ferritin (ng/ml) | 12,645 | 587** | 664*** | 11,035 | 8518** | 9235*** |
| 4155–21,135 | 402–2330 | 410–3785 | 6585–32,644 | 3390–11,833 | 5559–18,710 | |
| Platelets (× 104/mm3) | 12.4 | 11.7**** | 11.7*** | 14.5 | 21.9**** | 18.9*** |
| 7.6–17.2 | 7.7–13.1 | 7.7–13.3 | 12.1–18.5 | 20.2–32.2 | 13.3–21.8 | |
| AST (IU/l) | 666 | 119 | 161 | 296 | 63 | 89 |
| 382–949 | 61–290 | 63–438 | 78–681 | 53–92 | 61–425 | |
| TG (mg/dl) | 362 | 108* | 113* | 279 | 148* | 214* |
| 149–574 | 91–132 | 94–150 | 192–298 | 141–213 | 143–285 | |
| Fibrinogen (mg/dl) | 116 | 118**** | 118**** | 281 | 319**** | 294**** |
| 80–152 | 102–172 | 97–163 | 217–292 | 302–482 | 240–362 | |
| CRP (mg/dl) | 3.1 | 0.03**** | 0.03**** | 7.5 | 9.6**** | 7.6**** |
| 0.0–6.1 | 0.0–0.6 | 0.0–6.1 | 3.3–12.9 | 4.7–15.1 | 3.7–13.6 | |
Median values and IQR were shown. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001; AST Aspartic aminotransferase, TG Triglyceride, CRP C reactive protein